JCJohn J. Castellot

John J. Castellot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John J. Castellot has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Potential Anti-Tumor Drug: Co-Crystal 5-Fluorouracil-nicotinamide

    by Zhuyan Zhang, Nan Yu, Chang Xue, Shan Gao, Zhaopeng Deng, Min Li, Cong Liu, John Castellot, Siying Han

    5-Fluorouracil-nicotinamide (5-FU-NCM), a co-crystal with a 2D layer structure formed by hydrogen bonds, was synthesized by solvent evaporation and liquid phase-assisted grinding at room temperature. Compared to 5-FU alone, the results of solubility, oil–water partition coefficient, anti-tumor effect in vivo and vitro, acute toxicity, and pharmacokinetic parameters indicate that the co-crystal is a potential anti-tumor drug.


  • Open Access

    Opportunities and Challenges for Inter‐Professional One Health Education

    by John Castellot, Linda Afifi

    One Health is an interdisciplinary approach to optimizing health for humans, animals, and the environment at the local, national, and global level. It incorporates expertise from diverse fields—including human and veterinary medicine, environmental and biological sciences, engineering, public health, political science, urban planning, economics, sociology, epidemiology, and statistical modeling—to study and solve important challenges at the intersection of humans, animals, and the environment. While it is quite easy to get buy‐in from the various stakeholders in One Health, there are many barriers to incorporating inter‐professional education in this area. For example, many undergraduate institutions do not have public health, health profession, and engineering schools. Even universities like Tufts, which has these schools, face significant obstacles in integrating One Health into their curricula. Specific suggestions for overcoming these obstacles will be provided, including seed grant initiatives and mini‐symposia, along with a description of a highly successful inter‐professional One Health activity currently ongoing at our institution: a student‐driven, faculty coordinated “Comparative Anatomy Exchange Day”. This activity involves veterinary, medical, dental, physician assistant, and graduate students. The event is hosted at the medical school, which has a newly‐built Gross Anatomy laboratory. Since human anatomy labs have tables sized for humans, it is not possible to accommodate large animal cadavers. Thus, the focus is on a specific organ system such as the GI system. The vet students bring GI systems from large animals, including horses, cows, camelids, etc; smaller animal cadavers such as birds, cats, dogs, pigs, and sheep are also provided. The medical school provides 1–2 previously dissected cadavers that are especially good for illustrating the GI system. The morning session is devoted to students from the various professional schools presenting the GI system of the human and animal species via a series of short, pithy talks. Following lunch, all of the participants head to the Gross Anatomy laboratory where the human and animal cadavers are displayed. Students go from station to station as they wish. A student is in charge of describing the relevant anatomy at each station, with a small number of faculty available for questions. This activity has proven to be highly popular, despite the fact that it is an optional activity offered on a Saturday afternoon in late April—more than 130 students and faculty participated. Creating One Health activities that are fun, educational, and allow students from different professions to interact is a highly effective way to provide inter‐professional education around One Health. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .


  • Open Access

    A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma

    by Anne Chetty, Azeem Sharda, Rod Warburton, Ellen O Weinberg, Jinghui Dong, Min Fang, G Gary Sahagian, Tiangmeng Chen, Chang Xue, John J Castellot, et al.

    Background: Purinergic receptors control cell proliferation, apoptosis, migration, inflammation, and cytokine secretion. Increased expression of specific purinergic receptors is reported in asthma. The role of purinergic P2Y6 receptors (P2Y6R) in asthma is controversial. Hypothesis: P2Y6R activation in asthma improves pulmonary function and reduces inflammation and smooth muscle amount. Methods: Female mice (C57/BL6, age 30 days) were randomly assigned to receive intranasal house dust mite (HDM) antigen (40 or 80 µg) or saline, 5 days/week, for 6 weeks. Randomly selected subgroups received intraperitoneal P2Y6R agonist prodrug (GC021109; 10 or 100 μg/kg weight/dose) simultaneously with HDM. After 6 weeks, lung function was measured. Lung lavage fluid (LLF) was used to measure total cell count, total protein, and cytokines. Immunohistochemistry for alpha smooth muscle actin (α-SMA) was done. Airway wall thickness was measured on micro-computed tomography (micro-CT) images. Results: Pulmonary function testing revealed a HDM dose-dependent airway hyperresponsiveness. Airway resistance was increased 2-fold while compliance was decreased by 50% at the higher HDM dose (PP Conclusion: The P2Y6R prodrug GC021109 inhibited allergen-induced changes in pulmonary function, inflammatory responses, and airway and vascular smooth muscle mass. P2Y6R activation may be an effective therapeutic maintenance strategy in asthma.


  • CCN5 in alveolar epithelial proliferation and differentiation during neonatal lung oxygen injury

    by Najla Fiaturi, Joshua W. Russo, Heber C. Nielsen, John J. Castellot

    Lung immaturity is the major cause of morbidity and mortality in premature infants, especially those born Cysteine-rich protein 61/Connective tissue growth factor/Nephroblastoma-overexpressed protein) in the development of BPD. Cultured non-proliferating alveolar type II cells expressed low levels of CCN5 protein, and displayed higher levels during proliferation. siRNA targeting of CCN5 reduced alveolar type II cell proliferation and migration in cell culture. In a mouse model of hyperoxia-induced BPD, CCN5 protein was increased only in proliferating alveolar type I cells. Alveolar epithelial cells co-expressing markers of type II cells and type I cells also appeared. The results suggest that hyperoxic injury in immature lungs induces proliferation of type I cells and trans-differentiation of type II cells into type I cells. We propose that the mechanism of the injury response in BPD includes CCN5 expression. Study of CCN5 in neonatal alveolar injury will further our understanding of BPD pathophysiology while providing a mechanistic foundation for therapeutic approaches.


  • Matrix production and remodeling as therapeutic targets for uterine leiomyoma

    by Caitlin Fujisawa, John J. Castellot

    Uterine leiomyoma, commonly known as fibroids, is a benign neoplasm of smooth muscle in women. The incidence of clinically symptomatic fibroids in reproductive‐age women is approximately 20 %, with nearly 80 % of black women suffering from this condition. Symptoms include severe pain and hemorrhage; fibroids are also a major cause of infertility or sub‐fertility in women. Uterine leiomyoma consist of hyperplastic smooth muscle cells and an excess deposition of extracellular matrix, specifically collagen, fibronectin, and sulfated proteoglycans. Extracellular matrix components interact and signal through integrin‐β1 on the surface of uterine leiomyoma smooth muscle cells, provide growth factor storage, and act as co‐receptors for growth factor‐receptor binding. ECM and growth factor signaling through integrin‐β1 and growth factor receptors significantly increases cell proliferation and ECM deposition in uterine leiomyoma. Growth factors TGF‐β, IGF, PDGF, FGF and EGF are all shown to promote uterine leiomyoma progression and signal through multiple pathways to increase the expression of genes encoding matrix or matrix‐modifying proteins. Decreasing integrin expression, reducing growth factor action and inhibiting ECM action on uterine leiomyoma smooth muscle cells are important opportunities to treat uterine leiomyoma without use of the current surgical procedures. Both natural compounds and chemicals are shown to decrease fibrosis and uterine leiomyoma progression, but further analysis is needed to make inroads in treating this common women’s health issue.


  • Neuregulin-ErbB4 signaling in the developing lung alveolus: a brief review

    by Najla Fiaturi, John J. Castellot, Heber C. Nielsen

    Lung immaturity is the major cause of morbidity and mortality in premature infants, especially those born <28 weeks gestation. Proper lung development from 23–28 weeks requires coordinated cell proliferation and differentiation. Infants born at this age are at high risk for respiratory distress syndrome (RDS), a lung disease characterized by insufficient surfactant production due to immaturity of the alveoli and its constituent cells in the lung. The ErbB4 receptor and its stimulation by neuregulin (NRG) plays a critical role in surfactant synthesis by alveolar type II epithelial cells. In this review, we first provide an introduction to normal human alveolar development, followed by a discussion of the neuregulin and ErbB4-mediated mechanisms regulating alveolar development and surfactant production.


  • Dissociated presenilin-1 and TACE processing of ErbB4 in lung alveolar type II cell differentiation

    by Najla Fiaturi, Anika Ritzkat, Christiane E.L. Dammann, John J. Castellot, Heber C. Nielsen


  • The matricellular protein CCN5 regulates podosome function via interaction with integrin αvβ3

    by Ronald B. Myers, Lan Wei, John J. Castellot

    CCN proteins play crucial roles in cell motility, matrix turnover, and proliferation. In particular, CCN5 plays a role in cell motility and proliferation in several cell types; however, no functional binding proteins for CCN5 have been identified. In this study we report that CCN5 binds to the cell surface receptor integrin αvβ3 in vascular smooth muscle cells. Furthermore, this interaction takes place in podosomes, organelles known to degrade matrix and mediate motility. We show that CCN5 regulates the ability of podosomes to degrade matrix, but does not affect podosome formation. The level of CCN5 present in a podosome negatively correlates with its ability to degrade matrix. Conversely, knockdown of CCN5 greatly enhances the matrix-degrading ability of podosomes. These findings suggest that the antimotility effects of CCN5 may be mediated through the direct interaction of CCN5 and integrin αvβ3 in podosomes and the concomitant suppression of matrix degradation that is required for cell migration.


  • CCN5 Expression in mammals. III. Early embryonic mouse development

    by Ronald B. Myers, Kibibi Rwayitare, Lauren Richey, Janis Lem, John J. Castellot

    CCN proteins play crucial roles in development, angiogenesis, cell motility, matrix turnover, proliferation, and other fundamental cell processes. Early embryonic lethality in CCN5 knockout and over-expressing mice led us to characterize CCN5 distribution in early development. Previous papers in this series showed that CCN5 is expressed widely in mice from E9.5 to adult; however, its distribution before E9.5 has not been studied. To fill this gap in our knowledge of CCN5 expression in mammals, RT-PCR was performed on preimplantation murine embryos: 1 cell, 2 cell, 4 cell, early morula, late morula, and blastocyst. CCN5 mRNA was not detected in 1, 2, or 4 cell embryos. It was first detected at the early morula stage and persisted to the preimplantation blastocyst stage. Immunohistochemical staining showed widespread CCN5 expression in post-implantation blastocysts (E4.5), E5.5, E6.5, and E7.5 stage embryos. Consistent with our previous study on E9.5 embryos, this expression was not limited to a particular germ layer or cell type. The widespread distribution of CCN5 in early embryos suggests a crucial role in development.


  • CCN5: biology and pathophysiology

    by Joshua W. Russo, John J. Castellot

    CCN5 is one of six proteins in the CCN family. This family of proteins has been shown to play important roles in many processes, including proliferation, migration, adhesion, extracellular matrix regulation, angiogenesis, tumorigenesis, fibrosis, and implantation. In this review, we focus on the biological and putative pathophysiological roles of CCN5. This intriguing protein is structurally unique among the CCN family members, and has a unique biological activity profile as well.